Submitted by Anonymous (not verified) on 17 November 2026 - 10:02
Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0448/2022
Source:
